Amylin Pharmaceuticals Inc.
9360 Towne Centre Drive
Suite 110
San Diego,
CA 92121
United States - Map
Phone: 858-552-2200
Fax: 858-552-2212
Web Site: http://www.amylin.com
| Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly; Nasal Exenatide, a nasal spray formulation of exenatide for diabetes; Pramlintide and PYY 3-36 for the treatment of obesity; Leptin for the treatment of obesity and lipodystrophy; Pramlintide-Metreleptin combination product candidate for overweight or obese subjects; and second generation Amylinomimetic for weight loss. It sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers. The company has collaboration agreements with Eli Lilly and Company, as well as with Alkermes, Inc. to develop exenatide once weekly for diabetes; a joint research collaboration agreement with BioSeek, Inc. for discovery and development of novel peptide therapeutics for inflammatory conditions; and a joint research collaboration agreement with Xenome, Ltd. for discovery and development of novel peptide hormones for a range of metabolic and musculoskeletal diseases. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Dan Bradbury , 47
Chief Exec. Officer, Pres, Director and Member of Fin. Committee |
$
655.00K |
$
1.22M | Mr. Mark G. Foletta C.P.A., 48
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
$
409.00K |
$
883.00K | Dr. Orville G. Kolterman M.D., 61
Sr. VP R&D |
$
432.00K |
$
495.00K | Ms. Marcea Bland Lloyd , 60
Sr. VP of Legal & Corp. Affairs and Gen. Counsel |
$
470.00K | N/A | Mr. Roger Marchetti , 50
Sr. VP of HR & Information Management |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 
Profile
